Patents Assigned to Medivir AB
  • Patent number: 10822360
    Abstract: The invention provides compounds of the formula: R1 is OR11, or NR5R5?; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(?O)R6, O(C?O)R6 or O(C?O)OR6; R5? is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: November 3, 2020
    Assignee: MEDIVIR AB
    Inventors: Richard Bethell, Anders Eneroth, Bjorn Klasson, Fredrik Oberg
  • Patent number: 10723709
    Abstract: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo; R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro; R4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A1 is CH or N, A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N; R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O—C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4 alkoxy or F; R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as oste
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: July 28, 2020
    Assignee: MEDIVIR AB
    Inventors: Lourdes Salvador Oden, Magnus Nilsson, Pia Kahnberg, Bertil Samuelsson, Urszula Grabowska
  • Patent number: 10654877
    Abstract: The invention provides compounds of the formula: R1 is OR11, or NR5R5?; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(?O)R6, O(C?O)R6 or O(C?O)OR6; R5? is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: May 19, 2020
    Assignee: MEDIVIR AB
    Inventors: Richard Bethell, Anders Eneroth, Bjorn Klasson, Fredrik Oberg
  • Patent number: 10596220
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: March 24, 2020
    Assignee: Medivir AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • Patent number: 10336780
    Abstract: The invention provides compounds of the formula: R1 is OR11, or NR5R5?; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(?O)R6, O(C?O)R6 or O(C?O)OR6; R5 is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 2, 2019
    Assignee: MEDIVIR AB
    Inventors: Richard Bethell, Anders Eneroth, Bjorn Klasson, Fredrik Oberg
  • Patent number: 10329266
    Abstract: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo; R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro; R4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A1 is CH or N, A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N; R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O—C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4 alkoxy or F; R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as oste
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 25, 2019
    Assignee: MEDIVIR AB
    Inventors: Lourdes Salvador Oden, Magnus Nilsson, Pia Kahnberg, Bertil Samuelsson, Urszula Grabowska
  • Patent number: 10314881
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: June 11, 2019
    Assignee: Medivir AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • Patent number: 10258595
    Abstract: A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 16, 2019
    Assignee: Medivir AB
    Inventors: Todd W. Chappell, Keith A. Johnson
  • Patent number: 10172846
    Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: January 8, 2019
    Assignee: Medivir AB
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
  • Patent number: 10144750
    Abstract: The invention provides compounds of the formula: R1 is OR11, or NR5R5?; R2 is H or F; R5 is H, OH, C1-C6 alkyl, OH, C(?O)R6, O(C?O)R6 or O(C?O)OR6; R5? is H or C1-C6 alkyl; R6 is C1-C6 alkyl or C3-C7 cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: December 4, 2018
    Assignee: MEDIVIR AB
    Inventors: Richard Bethell, Anders Eneroth, Bjorn Klasson, Fredrik Oberg
  • Patent number: 10118941
    Abstract: Methods for the preparation of diastereomerically pure phosphoramidate prodrugs of nucleosides, and intermediates useful for the preparation are provided. The nucleosides are useful for the treatment of hepatitis C and cancer.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: November 6, 2018
    Assignee: MEDIVIR AB
    Inventors: Pedro Pinho, Staffan Torssell
  • Patent number: 10106571
    Abstract: The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: October 23, 2018
    Assignee: MEDIVIR AB
    Inventors: Genadiy Kalayanov, Staffan Torssell, Horst Wahling
  • Patent number: 9856265
    Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitroge
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 2, 2018
    Assignees: Janssen Sciences Ireland UC, Medivir AB
    Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Abdellah Tahri, Dominique Louis Nestor Ghislain Surleraux, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Asa Annica Kristina Rosenquist, Vladimir Ivanov, Mikael Pelcman, Anna Karin Gertrud Linnea Belfrage, Per-Ola Mikael Johansson, Sandrine Marie Helene Vendeville
  • Patent number: 9828408
    Abstract: The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 28, 2017
    Assignee: MEDIVIR AB
    Inventors: Genadiy Kalayanov, Staffan Torssell, Horst Wahling
  • Patent number: 9708332
    Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of RSV.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: July 18, 2017
    Assignee: MEDIVIR AB
    Inventors: Claudio Sturino, Teddy Halmos, Anne Decor, Martin Duplessis, Patrick Deroy, Araz Jakalian, Louis Morency, Cyrille Kuhn, Chantal Grand-Maitre, Martin Tremblay, Christian Brochu
  • Patent number: 9650388
    Abstract: There is provided Form 2 crystalline polymorph consisting of N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazin-1-yl)thiazol-4-yl]-benzamide monohydrochloride and N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazin-1-yl)thiazol-4-yl]benzamide hydrate monohydrochloride, its use as a medicament and methods for its preparation.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: May 16, 2017
    Assignee: MEDIVIR AB
    Inventors: Urszula Grabowska, Lourdes Salvador Oden, Victor M. Diaz Perez, Andrew Carr
  • Patent number: 9623022
    Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrog
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: April 18, 2017
    Assignees: Janssen Sciences Ireland UC, Medivir AB
    Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Abdellah Tahri, Dominique Louis Nestor Ghislain Surleraux, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Åsa Annica Kristina Rosenquist, Vladimir Ivanov, Mikael Pelcman, Anna Karin Belfrage, Per-Ola Mikael Johansson, Sandrine Marie Helene Vendeville
  • Patent number: 9540411
    Abstract: The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 10, 2017
    Assignee: MEDIVIR AB
    Inventors: Genadiy Kalayanov, Staffan Torssell, Horst Wahling
  • Patent number: 9481703
    Abstract: The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 1, 2016
    Assignee: MEDIVIR AB
    Inventors: Genadiy Kalayanov, Staffan Torssell, Horst Wahling
  • Patent number: 9428517
    Abstract: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo; R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro; R4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A1 is CH or N, A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N; R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O—C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4 alkoxy or F; R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as oste
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 30, 2016
    Assignee: MEDIVIR AB
    Inventors: Lourdes Salvador Oden, Magnus Nilsson, Pia Kahnberg, Bertil Samuelsson, Urszula Grabowska